Gilbert, N. F., Cannon, C. P., Lin, P. P. & Lewis, V. O. Gentle-tissue sarcoma. J. Am. Acad. Orthop. Surg. 17, 40–47. https://doi.org/10.5435/00124635-200901000-00006 (2009).
Brown, H. Ok., Schiavone, Ok., Gouin, F., Heymann, M. F. & Heymann, D. Biology of bone sarcomas and new therapeutic developments. Calcif. Tissue Int. 102, 174–195. https://doi.org/10.1007/s00223-017-0372-2 (2018).
Picci, P. Osteosarcoma (osteogenic sarcoma). Orphanet J. Uncommon Dis. 2, 6. https://doi.org/10.1186/1750-1172-2-6 (2007).
Schaefer, I. M. & Hornick, J. L. Diagnostic immunohistochemistry for tender tissue and bone tumors: An replace. Adv. Anat. Pathol. 25, 400–412. https://doi.org/10.1097/pap.0000000000000204 (2018).
Flores, G. & Grohar, P. J. One oncogene, a number of vulnerabilities: EWS/FLI focused therapies for Ewing sarcoma. J. Bone Oncol. 31, 100404. https://doi.org/10.1016/j.jbo.2021.100404 (2021).
Zöllner, S. Ok. et al. Ewing sarcoma-diagnosis, remedy, scientific challenges and future views. J. Clin. Med. 10, 1685. https://doi.org/10.3390/jcm10081685 (2021).
Sbaraglia, M., Bellan, E. & Dei Tos, A. P. The 2020 WHO classification of sentimental tissue tumours: Information and views. Pathologica 113, 70–84. https://doi.org/10.32074/1591-951x-213 (2021).
Tsukamoto, S., Mavrogenis, A. F., Kido, A. & Errani, C. Present ideas within the remedy of large cell tumors of bone. Cancers 13, 3647. https://doi.org/10.3390/cancers13153647 (2021).
Sobti, A., Agrawal, P., Agarwala, S. & Agarwal, M. Big cell tumor of bone—An summary. Arch. Bone Joint Surg. 4, 2–9 (2016).
Hu, P. et al. Recurrence charges and threat elements for major large cell tumors across the knee: A multicentre retrospective examine in China. Sci. Rep. 6, 36332. https://doi.org/10.1038/srep36332 (2016).
Miwa, S. et al. Therapeutic targets for bone and soft-tissue sarcomas. Int. J. Mol. Sci. 20, 170. https://doi.org/10.3390/ijms20010170 (2019).
Fu, T. et al. Spatial structure of the immune microenvironment orchestrates tumor immunity and therapeutic response. J. Hematol. Oncol. 14, 98. https://doi.org/10.1186/s13045-021-01103-4 (2021).
Buijs, A. et al. Elucidation of a novel pathogenomic mechanism utilizing genome-wide lengthy mate-pair sequencing of a congenital t(16;21) in a collection of three RUNX1-mutated FPD/AML pedigrees. Leukemia 26, 2151–2154. https://doi.org/10.1038/leu.2012.79 (2012).
Liu, X. et al. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. Environ. Well being Prev. Med. 24, 79. https://doi.org/10.1186/s12199-019-0835-3 (2019).
Han, Y., Liu, D. & Li, L. PD-1/PD-L1 pathway: Present researches in most cancers. Am. J. Most cancers Res. 10, 727–742 (2020).
Zheng, C. et al. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A scientific overview and meta-analysis. Drugs 97, e11004. https://doi.org/10.1097/md.0000000000011004 (2018).
Yoshida, Ok. et al. Scientific end result of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers. OncoTargets Ther. 12, 2513–2518. https://doi.org/10.2147/ott.s198421 (2019).
Liu, M. Y., Klement, J. D., Langan, C. J., van Riggelen, J. & Liu, Ok. Expression regulation and performance of PD-1 and PD-L1 in T lymphoma cells. Cell. Immunol. 366, 104397. https://doi.org/10.1016/j.cellimm.2021.104397 (2021).
Nunes-Xavier, C. E., Angulo, J. C., Pulido, R. & López, J. I. A crucial perception into the scientific translation of PD-1/PD-L1 blockade remedy in clear cell renal cell carcinoma. Curr. Urol. Rep. 20, 1. https://doi.org/10.1007/s11934-019-0866-8 (2019).
Bellucci, R. et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells by means of upregulation of PD-L1 expression. Oncoimmunology 4, e1008824. https://doi.org/10.1080/2162402x.2015.1008824 (2015).
Jorgovanovic, D., Tune, M., Wang, L. & Zhang, Y. Roles of IFN-γ in tumor development and regression: A overview. Biomark. Res. 8, 49. https://doi.org/10.1186/s40364-020-00228-x (2020).
Colak, S. & Ten Dijke, P. Concentrating on TGF-β signaling in most cancers. Developments Most cancers 3, 56–71. https://doi.org/10.1016/j.trecan.2016.11.008 (2017).
Haque, S. & Morris, J. C. Reworking development factor-β: A therapeutic goal for most cancers. Hum. Vaccines Immunother. 13, 1741–1750. https://doi.org/10.1080/21645515.2017.1327107 (2017).
Ritprajak, P. & Azuma, M. Intrinsic and extrinsic management of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 51, 221–228. https://doi.org/10.1016/j.oraloncology.2014.11.014 (2015).
Yi, M., Niu, M., Xu, L., Luo, S. & Wu, Ok. Regulation of PD-L1 expression within the tumor microenvironment. J. Hematol. Oncol. 14, 10. https://doi.org/10.1186/s13045-020-01027-5 (2021).
Pradhan, A. & Olsson, P. E. Intercourse variations in severity and mortality from COVID-19: Are males extra weak?. Biol. Intercourse Differ. 11, 53. https://doi.org/10.1186/s13293-020-00330-7 (2020).
Chen, J., Jiang, C. C., Jin, L. & Zhang, X. D. Regulation of PD-L1: A novel function of pro-survival signalling in most cancers. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 27, 409–416. https://doi.org/10.1093/annonc/mdv615 (2016).
Machado, I., López-Guerrero, J. A., Scotlandi, Ok., Picci, P. & Llombart-Bosch, A. Immunohistochemical evaluation and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma household of tumors (ESFT). Virchows Arch.: Int. J. Pathol. 472, 815–824. https://doi.org/10.1007/s00428-018-2316-2 (2018).
Mandai, M. et al. Twin faces of IFNγ in most cancers development: A job of PD-L1 induction within the willpower of pro- and antitumor immunity. Clin. Most cancers Res.: Off. J. Am. Assoc. Most cancers Res. 22, 2329–2334. https://doi.org/10.1158/1078-0432.ccr-16-0224 (2016).
Tong, L. J., Yamaguchi, N., Kita, M. & Imanishi, J. Enhancement of the expansion of human osteosarcoma cells by human interferon-gamma. Cell Struct. Funct. 17, 257–261. https://doi.org/10.1247/csf.17.257 (1992).
Lind, H. et al. Twin focusing on of TGF-β and PD-L1 through a bifunctional anti-PD-L1/TGF-βRII agent: Standing of preclinical and scientific advances. J. Immunother. Most cancers https://doi.org/10.1136/jitc-2019-000433 (2020).
Verrecchia, F. & Rédini, F. Reworking development factor-β signaling performs a pivotal function within the interaction between osteosarcoma cells and their microenvironment. Entrance. Oncol. 8, 133. https://doi.org/10.3389/fonc.2018.00133 (2018).
Crane, J. L., Xian, L. & Cao, X. Function of TGF-β signaling in coupling bone reworking. Strategies Mol. Biol. (Clifton, N.J.) 1344, 287–300. https://doi.org/10.1007/978-1-4939-2966-5_18 (2016).
Hagedorn, H. G., Bachmeier, B. E. & Nerlich, A. G. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Evaluate). Int. J. Oncol. 18, 669–681. https://doi.org/10.3892/ijo.18.4.669 (2001).
Vaezi, M. A. et al. Up-regulation of matrix metalloproteinase-9 in major bone tumors and its affiliation with tumor aggressiveness. Mol. Biol. Rep. 49, 9409–9427. https://doi.org/10.1007/s11033-022-07798-z (2022).
Batlle, E. & Massagué, J. Reworking development factor-β signaling in immunity and most cancers. Immunity 50, 924–940. https://doi.org/10.1016/j.immuni.2019.03.024 (2019).
Service provider, M. S. et al. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Most cancers Immunol. Immunother.: CII 56, 1037–1046. https://doi.org/10.1007/s00262-006-0257-0 (2007).
Hashimoto, Ok., Nishimura, S. & Akagi, M. Characterization of PD-1/PD-L1 immune checkpoint expression in osteosarcoma. Diagnostics (Basel, Switzerland) 10, 528. https://doi.org/10.3390/diagnostics10080528 (2020).
Castilho, J. L. et al. CD4/CD8 Ratio and most cancers threat amongst adults with HIV. J. Natl. Most cancers Inst. 114, 854–862. https://doi.org/10.1093/jnci/djac053 (2022).
Choi, J. H. & Ro, J. Y. The 2020 WHO classification of tumors of bone: An up to date overview. Adv. Anat. Pathol. 28, 119–138 (2021).
Dale, O. & Salo, M. The Helsinki Declaration, analysis tips and rules: Current and future editorial features. Acta anaesthesiologica Scandinavica 40, 771–772. https://doi.org/10.1111/j.1399-6576.1996.tb04530.x (1996).
Khademian, N. et al. Expression sample and scientific significance of β-catenin gene and protein in sufferers with major malignant and benign bone tumors. Sci. Rep. 12, 9488. https://doi.org/10.1038/s41598-022-13685-1 (2022).
Hosseini, A. et al. The native and circulating SOX9 as a possible biomarker for the analysis of major bone most cancers. J. Bone Oncol. 23, 100300. https://doi.org/10.1016/j.jbo.2020.100300 (2020).
Crowe, A. R. & Yue, W. Semi-quantitative willpower of protein expression utilizing immunohistochemistry staining and evaluation: An built-in protocol. Bio-protocol https://doi.org/10.21769/BioProtoc.3465 (2019).
Eghtedari, A. R. et al. Analysis of the expression sample and diagnostic worth of PPARγ in malignant and benign major bone tumors. BMC Musculoskelet. Disord. 23, 746. https://doi.org/10.1186/s12891-022-05681-3 (2022).
Hajian-Tilaki, Ok. Receiver working attribute (ROC) curve evaluation for medical diagnostic check analysis. Casp. J. Intern. Med. 4, 627–635 (2013).
World Medical Affiliation. World Medical Affiliation Declaration of Helsinki: Moral rules for medical analysis involving human topics. Jama 310, 2191–2194. https://doi.org/10.1001/jama.2013.281053 (2013).
